Utrecht, November 3, 2025 – TargED Biopharmaceuticals B.V., a clinical-stage biotechnology company developing next-generation targeted treatments for thrombotic diseases, today announced that first clinical and new preclinical data on its lead investigational thrombolytic fusion protein, TGD001, have been selected for oral presentations at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. The conference is being held in Orlando, Florida, from December 6 to 9, 2025.
“Being granted two oral presentations by ASH underscores the scientific rigor of our work and the transformative potential of TGD001,” said Kristof Vercruysse, Chief Executive Officer of TargED Biopharmaceuticals. “The presented data highlight TGD001’s differentiated mechanism of action and reinforce its potential as a first-in-class, targeted therapy to redefine the standard of care across a broad spectrum of thrombotic diseases.”
For the first time, TargED Biopharmaceuticals will present Phase 1 clinical data from its first-in-human, randomized, double-blind, placebo-controlled single-ascending dose study, evaluating the safety, tolerability, and pharmacokinetics (PK) of intravenously administered TGD001 in 34 healthy adult male participants across four dose cohorts.
Additionally, the company will share preclinical findings demonstrating the efficacy of TGD001 across multiple in vivo models of thrombosis, including acute ischemic stroke (AIS), pulmonary embolism, and thrombotic thrombocytopenic purpura (TTP), underscoring its potential as a universal thrombolytic.
ASH 2025 Oral Presentations:
Abstract Title: Novel von Willebrand Factor Targeting Thrombolytic TGD001 is Safe and Well Tolerated in a Phase 1 First-in-Human Trial
Abstract Number: #5938
Session: Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Old Dogs, New Tricks; Advances in Thrombotic Microangiopathy Diagnosis and Treatment
Date & Time: Monday, December 8, 2:45 PM – 4:15 PM ET – Presentation Time: 3:15 PM ET
Abstract Title: Novel von Willebrand Factor Targeting Thrombolytic TGD001 is Effective in Diverse Thrombotic Models, Demonstrating Its Potential as a Universal Thrombolytic
Abstract Number: #8142
Session: Vascular Biology, Thrombosis and Thrombotic Microangiopathies: Basic and Translational: Thrombosis and thrombotic microangiopathy: New mechanisms and new therapies
Date & Time: Saturday, December 6, 2:00 PM – 3:30 PM ET – Presentation Time: 3:00 PM ET
About TargED Biopharmaceuticals
TargED Biopharmaceuticals B.V. is a clinical-stage biotechnology company pioneering targeted enzyme delivery for improved treatment of thrombotic diseases. Founded in 2020 as a spin-off from the University Medical Center Utrecht, the company has raised more than €45 million to advance its pipeline and was awarded a prestigious blended finance grant from the European Innovation Council (EIC) Accelerator Program in 2025. For more information, please visit www.targedbio.com
About TGD001
TGD001 is a first-in-class, targeted thrombolytic designed to treat a broad range of thrombotic events. As an antibody-enzyme fusion protein, it combines an antibody fragment with high affinity for von Willebrand factor (VWF) with an enzyme that promotes site-specific clot breakdown. Unlike currently approved therapies, TGD001 leverages the ubiquitous presence of VWF in all clots, enabling broad clot lysis independent of fibrin content in clots. TGD001 has been evaluated in a Phase 1 first-in-human clinical trial and will be further developed for the treatment of acute ischemic stroke (AIS) and thrombotic microangiopathies (TMAs), including immune thrombotic thrombocytopenic purpura (iTTP).
Media Contact: info@targedbio.com